Haloperidol

When ATH:
N05AD01

Characteristic.

Microcrystalline or amorphous powder, white to light yellow. Practically insoluble in water, restrictedly soluble in alcohol, methylene chloride, ether. The saturated solution has a neutral to slightly acidic.

Pharmacological action.
Neuroleptic, antipsychotic, sedation, antiemetic.

Application.

Psychomotor agitation of various origins (craze, dementia, mental retardation, psihopatiâ, acute and chronic schizophrenia, Saint Martin's evil), delusions and hallucinations (paranoid state, acute psychosis), Huntington Gentingtona, anacatharsis, psychosomatic disorders, behavioral disorders in elderly and childhood, zaikanie, long-lasting and resistant to therapy hiccups and vomiting.

Contraindications.

Hypersensitivity (incl. and other. butyrophenone derivatives, sesame oil), CNS disorders, accompanied by pyramidal and extrapyramidal symptoms, depression, vapors, coma, pregnancy, lactation, Age to 3 years (for parenteral administration).

Restrictions apply.

Cardiovascular disease events decompensation, conduction disturbances of the heart muscle and kidney function.

Pregnancy and breast-feeding.

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects.

Headache, insomnia, or drowsiness (especially at the beginning of treatment), excitation, anxiety, alarm, fear, euphoria or depression, lethargy, epilepsy, эkzatserbatsiya psychosis and gallyutsinatsii. With more long-term use is ekstrapiramidnye violations (increased muscle tone, tremor, akinesia), incl. tardive dystonia, and neuroleptic malignant syndrome, followed by hyperthermia, muscle rigidity, loss of consciousness. When used in high doses is hyposalivation, nausea, vomiting, constipation or diarrhea, hypotension, tachycardia, arrhythmia, ECG changes, Sometimes the liver up to the development of jaundice, maculopapular skin changes and akneobraznye; rarely visual impairment (incl. acuteness), Cataract, retinopathy, laringospazm, bronchospasm, pain in the breasts, gynecomastia, menstrual disorders, impotence, increased libido, urinary retention, priapism, Sweating, alopecia, Temporary leukopenia or leukocytosis, erythropenia, hyperprolactinemia, Hyper- and hypoglycemia, giponatriemiya, photosensitivity.

Cooperation.

It enhances the effect of antihypertensive drugs, Opioid analgesics, Antidepressants, ʙarʙituratov, alcohol, weakens indirect anticoagulants-. Inhibits the metabolism of tricyclic antidepressants (their level increases in plasma) and increases the toxicity. With long-term appointment of carbamazepine in plasma levels of haloperidol drops (We need to increase the dose). In combination with lithium can cause a syndrome, such encephalopathy.

Overdose.

Symptoms: extrapyramidal disorders, hypotension, drowsiness, lethargy, in severe cases, coma, respiratory depression, shock.

Treatment: No specific antidote. Perhaps gastric lavage, the subsequent appointment of activated carbon (If overdose is associated with ingestion). When oppression breath-IVL, When pronounced decline in ad-introduction plazmozameshchath liquids, plasma, noradrenaline (but not adrenaline!), to reduce symptoms extrapiramidale disorders — Central and holinoblokatora means anti-parkinsonian N04.

Dosing and Administration.

B /, / m and inside. For acute psihozah adults is 5-10 mg in/m or/with the possible one- or re-introduction of the double in 30-40 minutes (the maximum daily dose is 30-40 mg). In acute alcoholic psychosis-in/5-10 mg (repeating, if necessary,), in the case of alcohol deliria in/in is 10-20 mg at a speed of 5-10 mg/min.

Tablets and solution for the reception inside adult appointed average daily dose 2,25 - 18 mg, increasing it until a sustainable therapeutic effect, followed by a transition to a lower, maintenance dose.

In the treatment of psychosis in children under 5 s start with 2 drops of oral solution 2 once a day, in children older 5 years - 5 drops 2 twice a day with a possible increase of the dose to achieve an effect. In the absence of clinical improvement during 1 month to continue therapy is not recommended.

Precautions.

With the development of tardive dyskinesia recommended a gradual reduction of the dose (up to the total abolition). During therapy, patients should refrain from activities potentially hazardous activities, require attention, rapid mental and motor responses.

Cooperation